Last reviewed · How we verify
Tislelizumab, Cisplatin, Gemcitabine
Tislelizumab, Cisplatin, Gemcitabine is a PD-1 inhibitor, platinum-based chemotherapy, nucleoside analog Small molecule drug developed by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. It is currently in Phase 3 development for Non-small cell lung cancer, metastatic or locally advanced, Esophageal squamous cell carcinoma, metastatic, Urothelial carcinoma, metastatic.
Tislelizumab is a PD-1 inhibitor monoclonal antibody that blocks the PD-1 receptor, Cisplatin is a platinum-based chemotherapy drug that interferes with DNA replication, and Gemcitabine is a nucleoside analog that inhibits DNA synthesis.
Tislelizumab is a PD-1 inhibitor monoclonal antibody that blocks the PD-1 receptor, Cisplatin is a platinum-based chemotherapy drug that interferes with DNA replication, and Gemcitabine is a nucleoside analog that inhibits DNA synthesis. Used for Non-small cell lung cancer, metastatic or locally advanced, Esophageal squamous cell carcinoma, metastatic, Urothelial carcinoma, metastatic.
At a glance
| Generic name | Tislelizumab, Cisplatin, Gemcitabine |
|---|---|
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | PD-1 inhibitor, platinum-based chemotherapy, nucleoside analog |
| Target | PD-1, DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Tislelizumab works by binding to the PD-1 receptor on T cells, preventing the PD-L1 ligand from binding and thereby inhibiting the immune checkpoint. Cisplatin works by forming platinum-DNA adducts that interfere with DNA replication and transcription, leading to cell death. Gemcitabine works by being incorporated into DNA, causing DNA strand breaks and inhibiting DNA synthesis, leading to cell death.
Approved indications
- Non-small cell lung cancer, metastatic or locally advanced
- Esophageal squamous cell carcinoma, metastatic
- Urothelial carcinoma, metastatic
- Gastric cancer, metastatic
- Colorectal cancer, metastatic
- Head and neck squamous cell carcinoma, metastatic
- Triple-negative breast cancer, metastatic
- Cervical cancer, recurrent or metastatic
- Hepatocellular carcinoma, advanced
- Non-small cell lung cancer, locally advanced or metastatic
Common side effects
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Anemia
- Thrombocytopenia
- Neutropenia
- Anorexia
- Weight loss
- Hypokalemia
Key clinical trials
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (PHASE2)
- Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma (PHASE3)
- Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma (PHASE3)
- Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma (PHASE3)
- Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC (PHASE1)
- 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma (PHASE3)
- Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tislelizumab, Cisplatin, Gemcitabine CI brief — competitive landscape report
- Tislelizumab, Cisplatin, Gemcitabine updates RSS · CI watch RSS
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University portfolio CI
Frequently asked questions about Tislelizumab, Cisplatin, Gemcitabine
What is Tislelizumab, Cisplatin, Gemcitabine?
How does Tislelizumab, Cisplatin, Gemcitabine work?
What is Tislelizumab, Cisplatin, Gemcitabine used for?
Who makes Tislelizumab, Cisplatin, Gemcitabine?
What drug class is Tislelizumab, Cisplatin, Gemcitabine in?
What development phase is Tislelizumab, Cisplatin, Gemcitabine in?
What are the side effects of Tislelizumab, Cisplatin, Gemcitabine?
What does Tislelizumab, Cisplatin, Gemcitabine target?
Related
- Drug class: All PD-1 inhibitor, platinum-based chemotherapy, nucleoside analog drugs
- Target: All drugs targeting PD-1, DNA
- Manufacturer: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer, metastatic or locally advanced
- Indication: Drugs for Esophageal squamous cell carcinoma, metastatic
- Indication: Drugs for Urothelial carcinoma, metastatic
- Compare: Tislelizumab, Cisplatin, Gemcitabine vs similar drugs
- Pricing: Tislelizumab, Cisplatin, Gemcitabine cost, discount & access